<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511914</url>
  </required_header>
  <id_info>
    <org_study_id>V58P1S</org_study_id>
    <secondary_id>2007-001404-20</secondary_id>
    <nct_id>NCT00511914</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008</brief_title>
  <official_title>A Phase III, Multicenter, Uncontrolled, Open-label Study to Evaluate Safety and Immunogenicity of a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture, Using the Strain Composition 2007/2008, When Administered to Adult and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell
      culture, using the strain composition 2007/2008, when administered to adult and elderly
      subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV).</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Pre and postvaccination geometric mean titers against all 3 strains were assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio After 1 Dose of the Cell Culture Derived Vaccine (cTIV)</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by hemagglutination inhibition (HI)assay using egg derived antigen in adults and elderly subjects.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22 / Day1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With HI Titer ≥40 After 1 Dose of Cell Culture Derived Vaccine (cTIV).</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>HI titer as assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70% for adults and &gt;60% for elderly subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentages of Subjects With Seroconversion or Significant Increase After 1 Dose of Cell Culture Derived Vaccine (cTIV).</measure>
    <time_frame>3 weeks postvaccination (Day 22)</time_frame>
    <description>Proportion of subjects with either seroconversion (antibody increase from &lt; 10 pre vaccination to ≥40 post vaccination) or significant increase (antibody titer of ≥10 pre vaccination and 4-fold antibody increase post vaccination).
According to the CHMP criteria, the percentages of subjects achieving seroconversion or significant increase should be &gt;40% for adults and &gt;30% for elderly subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Local and Systemic Reactions</measure>
    <time_frame>3 days postvaccination</time_frame>
    <description>To evaluate the safety and tolerability of cell culture derived vaccine (cTIV) in adults and elderly subjects in terms of number of subjects reporting local and systemic reactions after 1 vaccine dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Seasonal Influenza Vaccine</condition>
  <arm_group>
    <arm_group_label>cTIV (Adults)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cTIV (Elderly)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cTIV</intervention_name>
    <description>One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle</description>
    <arm_group_label>cTIV (Adults)</arm_group_label>
    <arm_group_label>cTIV (Elderly)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects eligible for enrollment into this study are male and female adults who were:

          1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior
             to study entry

          2. available for all the visits scheduled in the study and able to comply with all study
             requirements

          3. in good health as determined by:

               -  medical history

               -  physical examination

               -  clinical judgment of the investigator Written informed consent had to be obtained
                  from all the subjects before enrollment in the study after the nature of the
                  study had been explained.

        Exclusion Criteria:

        Subjects were not to be enrolled into the study if at least one of the following criteria
        was fulfilled:

          1. Any serious chronic or acute disease such as:

               1. Cancer (leukemia, lymphomas, neoplasm), except for benign or localized skin
                  cancer and non-metastatic prostate cancer not presently treated with chemotherapy

               2. Congestive heart failure

               3. Advanced arteriosclerotic disease

               4. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy and/or
                  acute exacerbation of a COPD within the last 14 days.

               5. Autoimmune disease (including rheumatoid arthritis), if under immunosuppressive
                  therapy (see below)

               6. Insulin dependent diabetes mellitus

               7. Acute or progressive hepatic disease

               8. Acute or progressive renal disease

               9. Severe neurological or psychiatric disorder

          2. History of any anaphylactic reaction and/or serious allergic reaction following a
             vaccination, a proven hypersensitivity to any component of the study vaccine or
             chemically related substances

          3. Known or suspected (or have a high risk of developing) impairment/alteration of immune
             function (excluding that normally associated with advanced age) resulting for example
             from:

               1. Receipt of immunosuppressive therapy (chronic therapy with immunosuppressive
                  drugs, any parenteral or oral corticosteroid (substitution dose in case of
                  absence of suprarenal function allowed) or cancer chemotherapy/radiotherapy)
                  within the last 2 months and for the full length of the study,

               2. Receipt of immunostimulants,

               3. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma
                  derivatives within the past 3 months and for the full length of the study,

               4. Suspected or known HIV infection or HIV-related disease.

          4. Known or suspected history of drug or alcohol abuse

          5. Bleeding diathesis or receive anticoagulants of the coumarin type

          6. Women who are pregnant or woman of childbearing potential unwilling to practice
             acceptable contraception for the duration of the study (21 days)

          7. Influenza immunization or laboratory confirmed influenza within the last 6 months and
             more than one influenza immunization within the past 12 months

          8. Immunization with any other vaccine and/or any investigational vaccine four weeks
             prior to study start

          9. Any significant acute or chronic infections requiring systemic antibiotic treatment or
             antiviral therapy within the last 7 days

         10. Fever (i.e. body temperature ≥ 38.0°C) within the past 3 days prior to study entry

         11. Simultaneous participation in another clinical study

         12. Any condition, which, in the opinion of the investigator, might prevent the subject
             from participation or interfere with the evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Vaccines</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Betriebsaerztlicher Dienst, Standort Marburg</name>
      <address>
        <city>Baldingerstrasse</city>
        <state>Marburg Hessen</state>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Z29, Blutspendezentrale, Gebaude Z29, Behringwerke</name>
      <address>
        <city>Emil-von-Behring-Str. 76</city>
        <state>Marburg</state>
        <zip>35041</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2007</study_first_submitted>
  <study_first_submitted_qc>August 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2007</study_first_posted>
  <results_first_submitted>December 10, 2012</results_first_submitted>
  <results_first_submitted_qc>December 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 17, 2013</results_first_posted>
  <last_update_submitted>January 18, 2013</last_update_submitted>
  <last_update_submitted_qc>January 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>cTIV (Adults)</title>
          <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="P2">
          <title>cTIV (Elderly)</title>
          <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>cTIV (Adults)</title>
          <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="B2">
          <title>cTIV (Elderly)</title>
          <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.4" spread="12.3"/>
                    <measurement group_id="B2" value="67.4" spread="4.7"/>
                    <measurement group_id="B3" value="52.3" spread="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
        <description>Pre and postvaccination geometric mean titers against all 3 strains were assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Elderly)</title>
            <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMT) After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
          <description>Pre and postvaccination geometric mean titers against all 3 strains were assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22" lower_limit="14" upper_limit="33"/>
                    <measurement group_id="O2" value="23" lower_limit="17" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="624" lower_limit="442" upper_limit="881"/>
                    <measurement group_id="O2" value="199" lower_limit="150" upper_limit="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36" lower_limit="24" upper_limit="56"/>
                    <measurement group_id="O2" value="80" lower_limit="53" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405" lower_limit="299" upper_limit="547"/>
                    <measurement group_id="O2" value="283" lower_limit="205" upper_limit="390"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.16" lower_limit="6.43" upper_limit="10"/>
                    <measurement group_id="O2" value="16" lower_limit="12" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="66" upper_limit="139"/>
                    <measurement group_id="O2" value="40" lower_limit="30" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Local and Systemic Reactions</title>
        <description>To evaluate the safety and tolerability of cell culture derived vaccine (cTIV) in adults and elderly subjects in terms of number of subjects reporting local and systemic reactions after 1 vaccine dose.</description>
        <time_frame>3 days postvaccination</time_frame>
        <population>Analysis was done on safety set.</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Elderly)</title>
            <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Local and Systemic Reactions</title>
          <description>To evaluate the safety and tolerability of cell culture derived vaccine (cTIV) in adults and elderly subjects in terms of number of subjects reporting local and systemic reactions after 1 vaccine dose.</description>
          <population>Analysis was done on safety set.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Redness/Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ( ≥ 38°C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio After 1 Dose of the Cell Culture Derived Vaccine (cTIV)</title>
        <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by hemagglutination inhibition (HI)assay using egg derived antigen in adults and elderly subjects.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22 / Day1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Elderly)</title>
            <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio After 1 Dose of the Cell Culture Derived Vaccine (cTIV)</title>
          <description>Geometric mean ratio (GMR) of Day 22 / Day 1 geometric mean antibody titers was assessed by hemagglutination inhibition (HI)assay using egg derived antigen in adults and elderly subjects.
The criterion is met according to European (CHMP) guideline if the mean geometric increase GMR (Day22 / Day1) in HI antibody titer is &gt;2.5 for adults and &gt;2.0 for elderly subjects.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 22 / Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="18" upper_limit="46"/>
                    <measurement group_id="O2" value="8.74" lower_limit="6.13" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22 / Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11" lower_limit="7.27" upper_limit="17"/>
                    <measurement group_id="O2" value="3.53" lower_limit="2.47" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B (Day 22 / Day1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="7.69" upper_limit="18"/>
                    <measurement group_id="O2" value="2.51" lower_limit="1.93" upper_limit="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With HI Titer ≥40 After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
        <description>HI titer as assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70% for adults and &gt;60% for elderly subjects.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Elderly)</title>
            <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With HI Titer ≥40 After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
          <description>HI titer as assessed by hemagglutination inhibition (HI) assay using egg derived antigen in adults and elderly subjects.
This criterion is met according to European (CHMP) guideline if the percentages of subjects achieving HI titers ≥40 is &gt;70% for adults and &gt;60% for elderly subjects.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="O2" value="37" lower_limit="26" upper_limit="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="88" upper_limit="99"/>
                    <measurement group_id="O2" value="96" lower_limit="87" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="39" upper_limit="64"/>
                    <measurement group_id="O2" value="72" lower_limit="59" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="90" upper_limit="100"/>
                    <measurement group_id="O2" value="96" lower_limit="87" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Prevaccination (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="6" upper_limit="24"/>
                    <measurement group_id="O2" value="28" lower_limit="18" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Postvaccination (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="68" upper_limit="88"/>
                    <measurement group_id="O2" value="66" lower_limit="53" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Subjects With Seroconversion or Significant Increase After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
        <description>Proportion of subjects with either seroconversion (antibody increase from &lt; 10 pre vaccination to ≥40 post vaccination) or significant increase (antibody titer of ≥10 pre vaccination and 4-fold antibody increase post vaccination).
According to the CHMP criteria, the percentages of subjects achieving seroconversion or significant increase should be &gt;40% for adults and &gt;30% for elderly subjects.</description>
        <time_frame>3 weeks postvaccination (Day 22)</time_frame>
        <population>Analysis was done on per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>cTIV (Adults)</title>
            <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
          <group group_id="O2">
            <title>cTIV (Elderly)</title>
            <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With Seroconversion or Significant Increase After 1 Dose of Cell Culture Derived Vaccine (cTIV).</title>
          <description>Proportion of subjects with either seroconversion (antibody increase from &lt; 10 pre vaccination to ≥40 post vaccination) or significant increase (antibody titer of ≥10 pre vaccination and 4-fold antibody increase post vaccination).
According to the CHMP criteria, the percentages of subjects achieving seroconversion or significant increase should be &gt;40% for adults and &gt;30% for elderly subjects.</description>
          <population>Analysis was done on per protocol set</population>
          <units>Percentages of Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79" lower_limit="68" upper_limit="88"/>
                    <measurement group_id="O2" value="67" lower_limit="55" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="60" upper_limit="82"/>
                    <measurement group_id="O2" value="40" lower_limit="28" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65" lower_limit="52" upper_limit="76"/>
                    <measurement group_id="O2" value="25" lower_limit="16" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All solicited adverse reactions were collected from Day 0 - Day 3. All unsolicited adverse events and Serious adverse events were collected throughout study period (Day 0- Day 21).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>cTIV (Adults)</title>
          <description>Adults 18-60 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
        <group group_id="E2">
          <title>cTIV (Elderly)</title>
          <description>Elderly subjects &gt;= 61 years of age received one dose of cell culture derived trivalent influenza vaccine (cTIV).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Posting Director</name_or_title>
      <organization>Novartis Vaccines and Diagnostics</organization>
      <email>RegistryContactVaccinesUS@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

